A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

Basit Öğe Kaydı
dc.authoridDemircioglu, Sinan/0000-0003-1277-5105
dc.authoridBASTURK, ABDULKADIR/0000-0003-1864-0316
dc.authoridMerter, Mustafa/0000-0002-0293-7388
dc.authoridSERIN, Istemi/0000-0003-1855-774X
dc.authoridTurgut, Burhan/0000-0001-5729-0043
dc.authoridEkinci, Omer/0000-0002-4636-3590
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.contributor.authorSerin, Istemi
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorEkinci, Omer
dc.contributor.authorCagliyan, Gulsum Akgun
dc.contributor.authorBasturk, Abdulkadir
dc.contributor.authorAras, Merih Reis
dc.contributor.authorDemircioglu, Sinan
dc.date.accessioned2024-10-29T17:59:34Z
dc.date.available2024-10-29T17:59:34Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
dc.identifier.doi10.4274/imj.galenos.2023.66742
dc.identifier.endpage125
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue2en_US
dc.identifier.startpage120
dc.identifier.trdizinid1179468
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2023.66742
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1179468
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14772
dc.identifier.volume24
dc.identifier.wosWOS:001000376900004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofIstanbul Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPolycythemia vera
dc.subjectruxolitinib
dc.subjectreal-life data
dc.subjectresponse
dc.subjectside effect
dc.titleA Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
dc.title.alternativeA Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu